# PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

Source: https://onco.cc/trials/nct06665100/  
OnCo record `nct06665100` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of PUL-042 in advanced solid tumours, run by Pulmotect, Inc., now recruiting.

## Summary

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) is a phase 2 interventional study registered as NCT06665100 by Pulmotect, Inc., with 100 participants planned, started 2025-06-27 and due to reach its primary completion in 2027-04. Interventions recorded: PUL-042 and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06665100
- Phase: 2
- Setting: Efficacy and Safety of PUL-042 Inhalation Solution in Reducing Lower Respiratory Tract Complications in Patients With Hematologic Malignancies and Recipients of Hematopoietic Stem Cell Transplantation (HSCT) With Documented Viral Infections With PIV, hMPV or RSV
- Sponsor: Pulmotect, Inc.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06665100: https://clinicaltrials.gov/study/NCT06665100

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06665100.json